BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced it has signed an agreement with Siemens’ PETNET Solutions Inc., a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., that grants the company the right to manufacture [F-18]MK-6240, an early stage investigational PET imaging agent, which is currently being evaluated to image neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
Under the terms of its agreement with Cerveau, Siemens’ PETNET Solutions Inc. will initially manufacture [F-18]MK-6240 clinical trial material at select U.S. radiopharmacies, with the possibility of expanding into additional locations.
“We are delighted that the MK-6240 clinical program will be supported by the extensive PET manufacturing and dispensing expertise of Siemens’ PETNET Solutions Inc.,” said Rick Hiatt, President and CEO of Cerveau Technologies, Inc. “At Cerveau, we are focused on providing information and technologies to researchers and clinicians to enable the improvement of brain health. We are excited by the opportunity to work with PETNET Solutions in providing access to this novel imaging agent to the broader scientific community.”
“Siemens' PETNET Solutions Inc. looks forward to closely collaborating with Cerveau. Our in-depth manufacturing expertise and large network of radiopharmacies will be key in supporting the availability of this investigational PET imaging agent,” said Barry Scott, CEO of Siemens’ PETNET Solutions Inc. “Our collaboration with Cerveau reinforces our commitment to help fight the world's most challenging diseases, such as Alzheimer's.”
Siemens’ PETNET Solutions Inc. operates the largest network of PET radiopharmaceutical drug manufacturing facilities and dispensing nuclear pharmacies, with over 50 locations worldwide. The company manufactures and dispenses PET radiopharmaceuticals for hospitals, clinics and research facilities worldwide.
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.
